Some pharmacological properties and subacute and chronic toxicity of tryptamide
Kleinrok, Z.; Sieklucka, M.; Rajtar, G.; Czuczwar, S.J.
Polish Journal of Pharmacology and Pharmacy 39(6): 737-747
1987
ISSN/ISBN: 0301-0244 PMID: 2972999 Document Number: 304152
Studies on Albino Swiss mice and Wistar rats have demonstrated that tryptamide is less ulcerogenic than phenylbutazone, and markedly inhibits intestinal periastalsis. Both compounds have a similar tendency to accumulate in the body. Tryptamide produces a smaller hypotension and stimulates the respiratory amplitude to a lesser extent than phenylbutazone in a vivisectional experiment. Studies on the subacute and chronic toxicity have demonstrated that tryptamide administered orally (po) and intraperitoneally (ip) for 3 weeks, and orally for 3 months neither affects the body weight gain or the mass of internal organs, nor changes the locomotor activity; only in rats it disturbs the motor coordination. After ip administration tryptamide shows a moderate depressant effect on the bone marrow, evidenced by a decline in the blood hemoglobin content and the number of erythrocytes and blood platelets. As those changes were more pronounced after a 3-week than a 3-month administration, the observed effects are apparently reversible.